Close menu




April 14th, 2020 | 10:47 CEST

Airbus, Royal Dutch Shell, Triumph Gold - Identifying and taking advantage of opportunities

  • Investments
Photo credits: pixabay.com

Globalisation is a competition with different interests. Access to knowledge and raw materials as well as a certain vertical range of manufacturing play an important role. Over many decades, the USA and Europe have occupied various leading positions in the field of role allocation. With the outbreak of the current Corona Crisis, the cards are being reshuffled. The dependence on China has grown to such an extent that the rest of the world is simply dependent on supplies from Asia. Supply chains to Asia are becoming a threat to the global balance. The need for action is obvious.

time to read: 1 minutes | Author: Mario Hose
ISIN: NL0000235190 , GB00B03MLX29 , CA8968121043

Table of contents:


    Strengthen Europe's aircraft manufacturers

    The European aircraft manufacturer Airbus Group cannot escape the effects of the global Corona Pandemic. Similar to its competitor Boeing, the share has been trading at a low level for several weeks. In February 2020, Airbus shares still cost more than EUR 137.00. Subsequently, the share price slipped to below EUR 50.00. Currently, the share is trading above EUR 60.00 again, bringing the company's valuation to over EUR 47 billion. During the same period, Boeing's share price collapsed from over USD 347.00 to below USD 96.00. At yesterday's closing price of around USD 147.00, the company is again valued at USD 83 billion.

    Oil and ESG

    The oil producer Royal Dutch Shell also recorded sharp price declines since the beginning of the year. The value of the shares has fallen from over EUR 27.00 to below EUR 11.00. At the current level of EUR 17.50, the company is valued at around EUR 135 billion. The stock of the Canadian oil producer Saturn Oil & Gas closed yesterday at CAD 0.11. The share price peaked at CAD 0.165 at the beginning of the year. The company is currently valued at around CAD 26 million and recently announced that around half of its output has been sold at a price of over CAD 65.00 per barrel by February 2021. The production of oil from countries where human rights and the environment are protected is becoming increasingly important in a better world.

    Gold for diversification

    Triumph Gold is a Canadian gold company focused on the exploration of its own areas in the Yukon. In the past, Triumph Gold has made numerous discoveries and Newmont Mining is one of the major shareholders of the listed company. Due to the recent development of the gold price to more than USD 1,700 per troy ounce, it can be expected that Triumph Gold will sooner or later become the focus of investors and potential buyers. At yesterday's closing price of CAD 0.17, the market capitalization is around CAD 18 million. Gold is one of the oldest and most secure currencies for investors in uncertain times.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read